Comparative effectiveness of gliclazide modified release versus sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes-Reference-Cited by-同舟云学术

Comparative effectiveness of gliclazide modified release versus sitagliptin as second‐line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes

Published:2020-09-09 Issue:12 Volume:22 Page:2417-2426
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Zaccardi Francesco¹^ORCID,Jacquot Emmanuelle²,Cortese Viviana³,Tyrer Freya¹,Seidu Samuel¹,Davies Melanie J.¹⁴^ORCID,Khunti Kamlesh¹^ORCID

Affiliation:

1. Diabetes Research Centre University of Leicester Leicester UK

2. Department of Pharmaco‐Epidemiology and Real World Evidence Institut de Recherches Internationales Servier Suresnes France

3. Servier Affaires Médicales Suresnes France

4. NIHR Leicester Biomedical Research Centre Leicester UK

Funder

Servier

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14169

Reference30 articles.

1. Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective

2. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

3. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

4. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Position of Gliclazide and Sulfonylureas in the Contemporary Treatment Paradigm for Type 2 Diabetes: A Scoping Review;Diabetes Therapy;2024-06-27

2. Flexible parametric methods for calculating life expectancy in small populations;Population Health Metrics;2023-09-13

3. The Role of Real-World Evidence in Treatment Decision-Making, Regulatory Assessment, and Understanding the Perspectives of People with Type 2 Diabetes: Examples with Gliclazide MR;Diabetes Therapy;2023-08-21

4. Results of a 12-month follow-up of patients with type 2 diabetes mellitus after hospitalization with COVID-19: gliclazide MR use in the hospital and metabolic status at the posthospital stage;Diabetes mellitus;2023-07-14

5. Roadmap for the Management of Type 2 Diabetes and Hypertension in the Middle East: Review of the 2022 EVIDENT Summit;Advances in Therapy;2023-05-26